Internal Medicine
Cluster RCT: Increasing the dietary sources of calcium and protein (by providing additional milk, yogurt, and cheese) reduced hip fractures and falls in older adults in residential care.
22 Oct, 2021 | 10:21h | UTCNews release: Increasing dairy intake reduces falls and fractures among older care home residents – British Medical Journal
Commentary on Twitter
Increasing intake of foods rich in calcium and protein such as milk, yoghurt, and cheese, reduces falls and fractures in older adults living in residential care, finds a randomised controlled trial published @bmj_latest today https://t.co/QzozG4Odjb
— BMJ Group (@bmj_company) October 21, 2021
RCT: Mirtazapine not better than placebo for the treatment of agitation in people with dementia and was possibly associated with increased mortality (7 vs.1 deaths, difference not statistically significant; p=0·065).
22 Oct, 2021 | 10:19h | UTCCommentary: Common antidepressant should no longer be used to treat people with dementia – University of Exeter
Radiotherapy: Clinical pearls for primary care.
22 Oct, 2021 | 10:12h | UTCRadiotherapy: Clinical pearls for primary care – Canadian Family Physician
Systematic Review: Malnutrition in Hospitalized Adults.
22 Oct, 2021 | 10:14h | UTCMalnutrition in Hospitalized Adults – Agency for Healthcare Research and Quality
See also:
An analysis of Scotland’s mortality in 114,000 SARS-CoV2–infected people revealed that the vaccine effectiveness against death from the Delta variant was 90% for the Pfizer vaccine and 91% for AstraZeneca.
21 Oct, 2021 | 10:15h | UTC
FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK.
21 Oct, 2021 | 10:09h | UTCFDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN
See also:
FDA OKs mixing COVID vaccines; backs Moderna, J&J boosters – Associated Press
FDA OKs Moderna, J&J boosters, along with ‘mix and match’ approach – NBC News
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
21 Oct, 2021 | 10:06h | UTCRelated:
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
COVID-19 pneumonia: pathophysiology and management.
21 Oct, 2021 | 10:12h | UTCCOVID-19 pneumonia: pathophysiology and management – European Respiratory Review
Guideline: Erectile Dysfunction.
21 Oct, 2021 | 10:01h | UTC
Opinion | Understanding of research results, evidence summaries and their applicability—not critical appraisal—are core skills of medical curriculum.
21 Oct, 2021 | 09:57h | UTC
Commentary on Twitter
https://twitter.com/lucasmorin_eolc/status/1450876923798765572
Cohort Study: Hypertensive disorders of pregnancy are associated with a 6-fold or higher increased risk of chronic hypertension in the first years following delivery.
21 Oct, 2021 | 09:51h | UTCEditorial: Impact of hypertensive disorders of pregnancy: lessons from CONCEPTION
Commentary on Twitter
Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study@escardio #EHJ #cardiotwitterhttps://t.co/OnJRP94W6v pic.twitter.com/N3dLNTD5XU
— EHJ Editor-in-Chief (@ehj_ed) October 17, 2021
Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.
20 Oct, 2021 | 10:27h | UTCCommentary: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University
Related:
A primer on what we know about mixing and matching Covid vaccines.
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
Study from Sweden assessing heterogenous vaccination in 3,445,061 individuals who received AZ as the first dose and either #pfizer, #moderna, or #AZ as second dose showed the following vaccine effectiveness:
AZ/Pfizer- 67%
AZ/Moderna- 79%
AZ/AZ- 50%https://t.co/UN0pey2kJ2— Yan Leyfman, MD (@YLeyfman) October 19, 2021
Should You Mix and Match Your Booster Shot?
20 Oct, 2021 | 10:25h | UTCShould You Mix and Match Your Booster Shot? – The Atlantic
Related:
A primer on what we know about mixing and matching Covid vaccines.
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19.
20 Oct, 2021 | 10:28h | UTCNews release: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases
[Preprint] Observational study in Brazil showed the J&J vaccine adjusted effectiveness was 50.9% against any symptomatic Covid-19, 72.9% for hospitalization, 92.5% for ICU admission, 88.7% for mechanical ventilation, and 90.5% for death.
20 Oct, 2021 | 10:24h | UTC
Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes.
20 Oct, 2021 | 10:20h | UTC
Covid-19: New mutation of Delta variant under close watch in UK.
20 Oct, 2021 | 10:21h | UTCCovid-19: New mutation of Delta variant under close watch in UK – BBC
Systematic Review: anti-interleukin-13 or anti-interleukin-4 agents may be appropriate for adults with moderate-to-severe uncontrolled asthma who have not responded to other treatments.
20 Oct, 2021 | 10:19h | UTC
Commentary on Twitter (thread – click for more)
Lead author David Evans said “Approximately five to ten percent of people with asthma experience symptoms that are severe or difficult-to-treat… [1/3] pic.twitter.com/Nw606oSrX0
— CochraneAirways (@CochraneAirways) October 19, 2021
Users’ guides to the medical literature: how to interpret and use a clinical practice guideline or recommendation.
20 Oct, 2021 | 10:09h | UTCHow to Interpret and Use a Clinical Practice Guideline or Recommendation: Users’ Guides to the Medical Literature – JAMA (free for a limited period)
Author Interview: How to Interpret and Use a Clinical Practice Guideline
RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.
20 Oct, 2021 | 10:13h | UTCTirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Related:
Review: Athletes and Hypertension.
20 Oct, 2021 | 09:52h | UTCAthletes and Hypertension – Current Cardiology Reports
Large observational study suggests Tramadol is associated with increased risk of adverse outcomes compared to Codeine.
20 Oct, 2021 | 10:11h | UTCAssociation of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes – JAMA (free for a limited period)
Editorial: Tramadol, Codeine, and Risk of Adverse Outcomes – JAMA (free for a limited period)
Cohort study: Acute urinary retention may be a clinical marker of occult prostate cancer and other urogenital, colorectal, and neurological cancers.
20 Oct, 2021 | 09:50h | UTCAcute urinary retention and risk of cancer: population based Danish cohort study – The BMJ
Commentary on Twitter
This study finds that a first diagnosis of acute urinary retention in patients aged 50 years or older was a clinical marker not only for prostate cancer but also for other urogenital cancers and colorectal and neurological cancershttps://t.co/0f1Z93cqR0 @dceaarhus
— The BMJ (@bmj_latest) October 19, 2021
Things We Do for No Reason: fluid restriction for the management of acute decompensated heart failure in patients with reduced ejection fraction.
20 Oct, 2021 | 10:00h | UTCThings We Do for No Reason™: Fluid Restriction for the Management of Acute Decompensated Heart Failure in Patients With Reduced Ejection Fraction – Journal of Hospital Medicine (free for a limited period)
Commentary on Twitter
🚨 Today’s Things We Do for No Reason ™️ from @JHospMedicine: Why do we think fluid restriction is important in managing ADHF? What’s the alternative? 💓
📢 Sound off in the replies why you do or don’t follow this practice. 👀#HeartFailure #ADHFhttps://t.co/QayZdqqNSd
— Society of Hospital Medicine (@SocietyHospMed) October 19, 2021
Long-term consequences of the misuse of ivermectin data.
19 Oct, 2021 | 09:56h | UTCLong-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases
Related:
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Commentary on Twitter
Ivermectin's data for Covid, checkered with inconsistencies, small/low quality clinical trials, and fraud, have long-term consequences for the drug's established and essential useshttps://t.co/NG6vpej8GP @TheLancetInfDis pic.twitter.com/Oz0FxUJetK
— Eric Topol (@EricTopol) October 18, 2021